1. Adelaide Research & Scholarship

Search


Current filters:
Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 21-30 of 33 (Search time: 0.003 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2007Functional analysis of the polymorphism - 211C>T in the regulatory region of the human ABCC3 geneGradhand, U.; Tegude, H.; Burk, O.; Eichelbaum, M.; Fromm, M.; Konig, J.
2004Impact of concentration and rate of intraluminal drug delivery on absorption and gut wall metabolism of verapamil in humansGlaeser, H.; Drescher, S.; Hofmann, U.; Heinkele, G.; Somogyi, A.; Eichelbaum, M.; Fromm, M.
2007Molecular mechanism of basal CYP3A4 regulation by hepatocyte nuclear factor 4a: Evidence for direct regulation in the intestineTegude, H.; Schnabel, A.; Zanger, U.; Klein, K.; Eichelbaum, M.; Burk, O.
2007Breast cancer treatment outcome with adjuvant tamoxifen relative to patient CYP2D6 and CYP2C19 genotypesSchroth, W.; Antoniadou, L.; Fritz, P.; Schwab, M.; Muerdter, T.; Zanger, U.; Simon, W.; Eichelbaum, M.; Brauch, H.
2009Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Münster protocolsStanulla, M.; Schaeffeler, E.; Moricke, A.; Coulthard, S.; Cario, G.; Schrauder, A.; Kaatsch, P.; Dordelmann, M.; Welte, K.; Zimmerman, M.; Reiter, A.; Eichelbaum, M.; Riehm, H.; Schrappe, M.; Schwab, M.
2008Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study GroupSchwab, M.; Zanger, U.; Marx, C.; Schaeffeler, E.; Klein, K.; Dippon, J.; Kerb, R.; Blievernicht, J.; Fischer, J.; Hofmann, U.; Bokemeyer, C.; Eichelbaum, M.
2010CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: Expanded polymorphism coverage improves risk stratificationSchroth, W.; Hamann, U.; Fasching, P.; Dauser, S.; Winter, S.; Eichelbaum, M.; Schwab, M.; Brauch, H.
2008Breast cancer risk reduction and membrane-bound catechol o-methyltransferase genetic polymorphismsJi, Y.; Olson, J.; Zhang, J.; Hildebrandt, M.; Wang, L.; Ingle, J.; Fredericksen, Z.; Sellers, T.; Miller, W.; Dixon, J.; Brauch, H.; Eichelbaum, M.; Justenhoven, C.; Hamann, U.; Ko, Y.; Bruning, T.; Chang-Claude, J.; Wang-Gohrke, S.; Schaid, D.; Weinshilboum, R.
2008A polymorphism in the TC21 promoter associates with an unfavorable tamoxifen treatment outcome in breast cancerRokavec, M.; Schroth, W.; Amaral, S.; Fritz, P.; Antoniadou, L.; Glavac, D.; Simon, W.; Schwab, M.; Eichelbaum, M.; Brauch, H.
2008Clinical relevance of CYP2D6 genetics for tamoxifen response in breast cancerBrauch, H.; Schroth, W.; Eichelbaum, M.; Schwab, M.; Harbeck, N.

Discover